Welcome to our dedicated page for Genmab A/S ADS news (Ticker: GMAB), a resource for investors and traders seeking the latest updates and insights on Genmab A/S ADS stock.
Genmab A/S (NASDAQ: GMAB) is a pioneering biotechnology company founded in February 1999 and headquartered in Copenhagen, Denmark. Established by Florian Schönharting, the company focuses on the development and commercialization of innovative antibody therapeutics for the treatment of cancer and other serious diseases.
Genmab's proprietary antibody technologies include DuoBody, HexaBody, DuoHexaBody, and HexElect. These cutting-edge platforms have enabled the creation of multiple high-impact drugs in partnership with leading pharmaceutical companies:
- Darzalex: Developed with Johnson & Johnson, this drug is a standard treatment for multiple myeloma.
- Tepezza: Partnered with Horizon, this medication targets thyroid eye disease.
- Kesimpta: Developed with Novartis, it treats relapsing multiple sclerosis.
- Rybrevant: Another collaboration with Johnson & Johnson, this drug addresses non-small cell lung cancer (NSCLC).
- Tivdak: In partnership with Seagen, Tivdak is used for the treatment of cervical cancer.
- Epkinly: Partnered with AbbVie, Epkinly targets diffuse large B-cell lymphoma.
In addition to these marketed products, Genmab has a robust pipeline of candidates targeting various oncologic indications. The company's focus on antibody therapeutics places it at the forefront of biotechnological innovation, continually seeking better outcomes for patients worldwide.
Genmab's financial health is bolstered by its successful alliances and product sales, positioning it strongly for future growth and development. Investors and stakeholders can stay informed about the latest updates and relevant information regarding Genmab's performance, events, and developments through regular news releases.
Genmab A/S (Nasdaq: GMAB) announced the submission of a Japan New Drug Application (JNDA) for epcoritamab, an investigational bispecific antibody targeting relapsed/refractory large B-cell lymphoma (LBCL). This submission is backed by results from Japanese and global phase 2 clinical trials. Epcoritamab's ongoing development involves collaboration with AbbVie, with shared responsibilities for commercialization in the U.S. and Japan. The treatment shows promise as a therapeutic option for patients requiring alternative therapies.
Genmab A/S (Nasdaq: GMAB) has announced promising results from multiple clinical trials involving epcoritamab, an investigational bispecific antibody targeting B-cell malignancies. Notable findings include an 85% overall response rate in a phase 1b/2 trial for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and high response rates in follicular lymphoma. Epcoritamab is co-developed with AbbVie and is undergoing regulatory review, with an FDA action date of May 21, 2023. The breadth of data presented at the American Society of Hematology annual meeting underscores Genmab's commitment to addressing critical treatment needs.
Genmab (NASDAQ: GMAB) announced the acceptance of 19 abstracts for the 64th Annual Meeting of the American Society of Hematology (ASH) taking place December 10-13, showcasing investigational therapies including epcoritamab. The data will feature four oral presentations on epcoritamab's efficacy in treating various B-cell malignancies. The company will present early data on GEN3014 and GEN3017. A 2022 R&D Update and ASH Data Review meeting is scheduled for December 12.
Genmab has submitted a Biologics License Application (BLA) to the U.S. FDA for epcoritamab, a bispecific antibody targeting relapsed/refractory large B-cell lymphoma. AbbVie has also validated a Marketing Authorization Application (MAA) for epcoritamab with the European Medicines Agency (EMA). These submissions stem from the EPCORE NHL-1 phase 2 trial, showing the drug's safety and efficacy in treating CD20+ mature B-cell non-Hodgkin lymphoma, a significant medical need exists for these patients. The joint development with AbbVie aims to bring new therapeutic options to market.
FAQ
What is the current stock price of Genmab A/S ADS (GMAB)?
What is the market cap of Genmab A/S ADS (GMAB)?
What does Genmab A/S specialize in?
What are Genmab's proprietary antibody technologies?
Which companies has Genmab partnered with?
What is Darzalex?
What other products are in Genmab's portfolio?
What is Tepezza used for?
Where is Genmab headquartered?
How does Genmab's financial condition look?
When was Genmab founded?
What is the focus of Genmab's pipeline candidates?
